A product name alone cannot establish what will arrive, whether it is authorised for your market, or whether the shipment meets the buyer’s quality requirements. By the end, you will have a practical specification, verification, receiving and supplier-comparison framework for ordering afatinib 40 mg tablets safely and lawfully.
Key takeaways
- Confirm afatinib 40 mg film-coated tablets and oral administration.
- Request batch records, certificates of analysis and stability data.
- Verify import licences, product registration and sale authorisation.
- Specify temperature limits, shipping records and receiving inspection steps.
What must an Afanat 40 supplier specification sheet contain?
The sheet must identify the medicine as afatinib 40 mg film-coated tablets for oral administration. “Afanat 40” alone is not proof of composition, strength or regulatory identity.
Record these physical details before issuing the purchase order:
- Exact tablet composition, including excipients or a clear tablet-composition statement
- Tablets per pack and primary pack type, such as blister or bottle
- Carton configuration, tamper evidence and desiccant requirement where applicable
- Labelled storage statement, protection from moisture or light, and shelf life
- Manufacturer, marketing-authorisation holder, manufacturing site, packing site, country of manufacture and country of registration
- Product status: original brand, licensed generic or trade-name product
- Exact label version and pack artwork, not catalogue wording
A 40 mg pack is not an automatic substitute for another presentation. The comparison belongs in the specification.
| Presentation | What to verify | Procurement consequence |
|---|---|---|
| 40 mg | Afatinib strength and approved pack | Suitable only when 40 mg is prescribed |
| Reduced strength | Available 10 mg dose steps and 20 mg lowest listed dose | Required after clinically directed dose reduction |
| Other strength | Label, pack count and regulatory identity | Do not substitute without approval |
Ask for the product specification, approved package insert, sample carton and photographs of the primary pack. Reconcile the brand, active ingredient, strength, manufacturer, batch number, expiry date and regulatory identity across every document.
Searches for af anat 40 pharmaceutical supplier and af anat 40 supplier can return different listings. Approve the product only when the physical pack and regulatory records agree.
Which clinical and molecular details must procurement verify?
Procurement can approve the clinical match only after a confirmed molecular result and oncology prescriber’s assessment; purchasing staff must not select treatment from a test result alone.
Require the pathology or molecular report to identify:
- Tested specimen, assay platform, report date and laboratory
- Quality-control results and exact EGFR alteration wording
- Whether the finding is an EGFR exon 19 deletion, L858R, uncommon alteration, non-classical alteration or alteration outside the approved indication
Every EGFR result is not equivalent. Do not treat an exon 19 deletion or L858R as interchangeable with an unapproved or weakly established alteration.
The supplier file must contain the destination-market package insert. Use it to verify administration schedule, food timing, dose-adjustment framework, handling instructions and available strengths; do not invent directions or substitute another market’s label. Confirm the insert’s warnings and monitoring requirements for diarrhoea, rash or acneiform dermatitis, stomatitis, paronychia, dry skin, hepatic function and cardiac function.
Check P-glycoprotein inhibitors and inducers against the label’s interaction instructions, including any dose or administration separation.
A certificate of analysis confirms batch quality tests, not mutation eligibility, dosing or interaction management. An afatinib tablet supplier must also distinguish products by clinical scope:
| Drug | Target or coverage | Procurement comparison |
|---|---|---|
| Afatinib | Irreversible ErbB-family inhibitor; label-defined EGFR mutations | Confirm indication, strength and dose |
| Gefitinib or erlotinib | EGFR tyrosine-kinase inhibition | Different mutation coverage, dose and indications |
| Osimertinib | EGFR-directed therapy with distinct label-defined coverage | Not an automatic substitute |
Treat dose, target, mutation coverage and indication as separate checks.
Which regulatory documents prove the product can be imported and sold?
A quotation becomes legally usable only after you prove that Afanat 40 can enter and be sold in the destination market. Manufacture or export from India does not establish legal sale in Saudi Arabia or elsewhere.
For Afanat 40 oncology procurement, request these documents:
- Approved product specification and package insert
- Batch-specific certificate of analysis (CoA)
- Certificate of Pharmaceutical Product (CPP) or destination-equivalent document
- Certificate of origin
- GMP evidence
- Manufacturing and packing-site names and addresses
- Batch-release evidence
- Stability data
- Export documents
- Destination-market registration or import authorisation
Confirm the CoA; do not assume it exists because a supplier claims “WHO-GMP.” The batch record must address identity, assay, related substances, dissolution, dosage-unit uniformity, moisture or water, microbial quality where specified, and compliance with the registered specification. GMP status alone does not prove that this batch passed those tests.
| Document | What it establishes | What it does not establish |
|---|---|---|
| CoA | This batch meets its finished-product specification | Permission to sell in the destination |
| CPP or equivalent | Regulatory status in the issuing country | Local registration |
| Import authorisation | Permission for the named shipment or product | Clinical suitability |
| Stability report | Shelf life under tested conditions | Validity after unauthorised repacking |
Check whether the importer needs a marketing authorisation, prescription-medicine licence, import permit, pharmacovigilance arrangement, or local-language label. Stability data must match the 40 mg strength, container-closure system and storage conditions, including long-term, accelerated and relevant intermediate studies under ICH Q1A(R2). Confirm whether the product is registered, licensed, or merely available for export.
How should you specify transport, delivery and receiving controls?
A sealed carton is not proof of acceptable transport. Require the supplier to state the labelled storage temperature, protection from moisture and light, transport conditions, excursion policy, and temperature-monitoring method before af anat oncology procurement is approved.
1. Put the exact primary pack on the purchase order: Afanat 40 afatinib 40 mg film-coated tablets, blister or bottle type, tablets per pack, cartons per shipper, desiccant requirement if applicable, tamper evidence, and serialisation or aggregation data where the destination market requires it.
State the minimum remaining shelf life at dispatch and reject short-dated stock below that threshold.
2. Record freight method, insurance responsibility, customs responsibility, Incoterm, delivery lead time, and the logger type, placement, calibration status, and result required with each shipment. Define who investigates a temperature or moisture excursion and who authorises release or rejection.
3. On receipt, match the carton against the purchase order, invoice, packing list, certificate of analysis, and shipping records. Capture product name, strength, dosage form, manufacturer, batch number, printed manufacturing date, expiry-date format, quantity, seal condition, storage statement, and temperature-logger result.
4. Reconcile authorised distribution records, printed batch and expiry details, tamper evidence, and serialisation data where required. A changed bottle, blister, or repacking arrangement can invalidate the original stability evidence unless the configuration is authorised and supported by data.
Do not release stock when the seal, batch, expiry, storage statement, or transport record conflicts across documents. Quarantine it pending documented investigation.
How do you compare an Afanat 40 supplier before placing an order?
A stronger Afanat 40 supplier proves product identity before offering a low price. Confirm that the pack is an afatinib 40 mg film-coated tablet, then reconcile its brand, manufacturer, marketing-authorisation holder, manufacturing country, batch number and expiry date with the label and regulatory records.
Send this enquiry to every Afanat 40 supplier:
- State available stock, exact blister or bottle presentation, tablets per pack, batch and expiry, remaining shelf life, manufacturer, marketing-authorisation holder, manufacturing country, sample label and package insert.
- Request the batch-specific certificate of analysis, certificate of pharmaceutical product, GMP evidence, registration status, shipping conditions, lead time, minimum order quantity, quotation validity, payment terms, Incoterm, freight method, insurance, customs role, complaint contact, recall process, pharmacovigilance support and replacement terms.
Score the replies against the same criteria:
| Supplier | What to verify | Why it matters |
|---|---|---|
| Manufacturer traceability | Site, country, batch-release evidence | Prevents an untraceable oncology product entering stock |
| Regulatory status | Registration or import authorisation in the destination | Export availability does not prove legal sale |
| Documentation quality | CoA covering identity, assay, dissolution, uniformity and related substances | A WHO-GMP claim alone does not prove batch compliance |
| Continuity and response | Stock history, lead time and complete answers | Delays and evasive replies create treatment and compliance risk |
An afatinib tablet supplier must not substitute brands, manufacturers or strengths without checking local rules, the purchase order, prescriber or hospital policy and the destination label. A different afatinib strength is not an automatic substitute.
Evaluate NIBA HEALTHCARE by its exact-product identification, verifiable batch documents, export responsibility and compliant-delivery support—not its Riyadh location alone. Record why the supplier and presentation were approved.
Related product
![]() | AFATINIB Afanat 40 Tablet is used in the treatment of non-small cell lung cancer. View product → |
Frequently asked questions
What must an Afanat 40 supplier specification sheet contain?
It must identify Afanat 40 as afatinib 40 mg film-coated tablets for oral administration, with the composition, dosage form, pack size, batch details and storage conditions.
Which clinical and molecular details must procurement verify?
Verify the active ingredient, 40 mg strength, tablet formulation, intended oral route, approved indication, molecular identity and supporting quality documents such as assay and dissolution results.
Which regulatory documents prove the product can be imported and sold?
Request the manufacturer’s licence, product registration or marketing authorisation, certificate of pharmaceutical product, certificate of analysis and import documentation required by the destination market.
How should you specify transport, delivery and receiving controls?
Set written temperature, humidity, packaging, delivery-time and excursion-reporting requirements, then inspect seals, batch numbers, expiry dates and shipping records on receipt.
How do you compare an Afanat 40 supplier before placing an order?
Compare regulatory status, batch evidence, remaining shelf life, minimum order quantity, lead time, packaging, complaint handling and the supplier’s ability to document transport conditions.
